Health Care

SACRAMENTO, Calif., June 5, 2026 /PRNewswire/ -- Global law firm Greenberg Traurig, LLP continues the growth of its Health Care & FDA Practice with the...

Special meeting will allow shareholders to vote on share consolidation to support potential uplisting to a U.S. stock exchange

Special meeting will allow shareholders to vote on share consolidation to support potential uplisting to a U.S. stock exchange

NOVATO, Calif., June 5, 2026 /PRNewswire/ -- Brayton Purcell LLP is bringing attention to a June 4, 2026 article by KQED News journalist Farida Jhabvala...

TAMPA, Fla., June 5, 2026 /PRNewswire/ -- This week, 7-year-old Mikey Hartnett and his parents joined leaders from BayCare and St. Joseph's Children's Hospital...

Informations relatives au nombre total de droits de vote et d’actions composant le capital

ALEXANDRIA, Va., June 5, 2026 /PRNewswire/ -- The American Council of the Blind (ACB) is pleased to announce the opening of registration for the...

Luxury fitness and content platform surpasses 40,000 annual client visits, records 139% attendance growth, and explores strategic expansion opportunities beyond Sag HarborSAG HARBOR, N.Y.,...

Cosmos Health launches Oliv18™, a USDA and EU certified whole olive polyphenol supplement targeting cardiovascular and antioxidant categories.

SARASOTA, Fla., June 5, 2026 /PRNewswire/ -- Pines of Sarasota Healthcare, LLC experienced a data security incident that involved personal and / or protected...

DALLAS, June 05, 2026 (GLOBE NEWSWIRE) -- Taysha Gene Therapies, Inc. (Nasdaq: TSHA) (Taysha or the Company), a clinical-stage biotechnology company focused on advancing adeno-associated virus (AAV)-based gene therapies for severe monogenic diseases of the central nervous system (CNS), today announced that, on June 1, 2026, the Compensation Committee of Taysha's Board of Directors granted four new employees, in the aggregate, restricted stock units (RSUs) representing 714,700 shares of the Company’s common stock and an option to purchase 468,600 shares of the Company's common stock in connection with their employment. The RSUs and stock option were granted under the Taysha Gene Therapies, Inc. 2023 Inducement Plan as an inducement material to the individuals entering employment with Taysha in accordance with Nasdaq Listing Rule 5635(c)(4).

BOSTON, June 5, 2026 /PRNewswire/ -- Haemonetics Corporation (NYSE: HAE), a global medical technology company focused on delivering innovative solutions designed to improve patient...

Beer Connoisseur's Editor's Choice roundup spotlights The Hemp Doctor's THC seltzers, drink powders, and mixers for their quality and potency options.